Keywords: Threshold Pharma, TH-302, Pancretic cancer, Merck KGaA, Erbitux, NSCLC, MAA withdrawn, GlaxoSmithKline, Synflorix, Pneumonia, EU

News briefs from Threshold, Merck KGaA and GSK

Article | 18 September 2012

Print This

US biotech firm Threshold Pharmaceuticals (Nasdaq: THLD) said yesterday that data from a Phase IIb trial of TH-302 in patients ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in